Tandem Diabetes Care, Inc.
TNDMHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Tandem Diabetes Care, Inc. (TNDM) is listed under Medical Devices. At a $1.38B market cap, Tandem Diabetes Care, Inc. ranks as a small-cap company within healthcare. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.
Market Cap
$1.38B
Beta
1.56
P/E (TTM)
—
P/E (Fwd)
116.58
EPS (TTM)
$-0.90
EPS (Fwd)
$0.17
ROE
-48.0%
ROA
-2.6%
Cash
$456.0M
Total Debt
$739.3M
Free CF
-$43.9M
52W Change
58.4%
Annual Financials
Cash vs Debt
Where TNDM stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, TNDM finished 11.99% above its 150-day moving average ($19.27) and 9.99% above its 200-day moving average ($19.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TNDM overbought or oversold?
At the August 26, 2026 close, TNDM's RSI(14) was 59.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $456.0M in cash, though total debt stands at $739.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$43.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -48.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $801.2M (2022) to $1.01B (2025), reflecting a 27% increase over the period.
A beta of 1.56 means TNDM is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Tandem Diabetes Care, Inc.'s trajectory.